Brief: HLS Therapeutics Announces Q3 Fiscal 2023 Financial Results And Renewal Of Normal Course Issuer Bid
09/11/2023 12:21
Nov 9 (Reuters) - Hls Therapeutics Inc HLS.TO :
* HLS THERAPEUTICS ANNOUNCES Q3 FISCAL 2023 FINANCIAL
RESULTS AND
RENEWAL OF NORMAL COURSE ISSUER BID
* SAYS Q3 2023 REVENUE WAS $16.0 MILLION, COMPARED TO $15.7
MILLION IN Q3 2022
* QTRLY LOSS $0.21 PER SHARE
* Q3 REVENUE VIEW $16.3 MILLION -- LSEG IBES DATA
Source text for Eikon: ID:nCNWb0kGFa
Further company coverage: HLS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HLS Therapeutics
See all newsCanada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group
Canada's HLS Therapeutics Q1 revenue rises on Vascepa growth, reaffirms 2026 guidance
Canada's HLS Therapeutics Q4 revenue slightly beats on Vascepa strength
Brief: Esperion Partner announces HLS Therapeutics received approval Of NILEMDO for the reduction of LDL-cholesterol in canadians at risk of cardiovascular disease
Brief: HLS Therapeutics announces Health Canada approval of NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease